BG Pulse Journal USA
ISSN:1947-2536 http://www.bgpulseusa.com/index.php/bg
BG PULSE JOURNAL

UDC 618.17-002-036.1-07-08

CLINICAL-DIAGNOSTIC FEATURES AND MODERN TREATMENT PRINCIPLES OF MENSTRUAL CYCLE DISORDERS IN WOMEN OF REPRODUCTIVE AGE

Ubaydullayeva Shinar Azimbayevna
Axtamova Nilufar Akbarjanovna
Samarkand State Medical University, Samarkand, Uzbekistan
https://doi.org/10.5281/zenodo.20391435

Annotation

Background: Menstrual cycle disorders among women of reproductive age represent a multifaceted gynecological, endocrine, and metabolic challenge. These irregularities—ranging from oligomenorrhea and amenorrhea to abnormal uterine bleeding—are primary contributors to female infertility, metabolic syndrome, and significant reductions in overall quality of life. Despite the high prevalence of these conditions, traditional therapeutic paradigms have often relied heavily on symptom management rather than addressing the root pathophysiological causes.

Aim: This prospective clinical study aims to comprehensively evaluate the clinical and diagnostic features of menstrual cycle disorders and compare the long-term efficacy of modern, etiologically targeted, and personalized treatment protocols against standard symptomatic therapeutic approaches.

Materials and Methods: A prospective clinical investigation was conducted involving 80 women of reproductive age (18–35 years) suffering from chronic menstrual cycle abnormalities. Participants were systematically divided into two cohorts: a modern method group (n=40), which received targeted hormonal and metabolic correction based on extensive endocrine and ultrasonographic profiling, and a control group (n=40), which was managed using standard conventional protocols (primarily combined oral contraceptives).

Results: The comprehensive diagnostic phase revealed that Polycystic Ovary Syndrome (PCOS) and insulin resistance were the dominant etiological drivers. Post-treatment evaluations after six months demonstrated that the modern targeted approach yielded statistically significant improvements in hormonal normalization (reducing the LH/FSH ratio from 2.38 to 1.11) and metabolic stabilization (reducing fasting insulin from 14.5 μU/mL to 8.2 μU/mL). Furthermore, the modern group exhibited a significantly faster and higher rate of spontaneous ovulatory cycle restoration compared to the control group.

Conclusion: The shift from generalized symptomatic management to precision gynecological endocrinology significantly accelerates the restoration of normal ovulatory cycles, corrects underlying metabolic dysfunctions, and preserves long-term reproductive health.

Keywords: menstrual cycle disorders, reproductive endocrinology, hypothalamic-pituitary-ovarian axis, Polycystic Ovary Syndrome (PCOS), insulin resistance, targeted therapy, ovulatory dysfunction, hyperandrogenism.

Introduction

The Physiological Framework of the Menstrual Cycle

The normal menstrual cycle is a highly orchestrated physiological continuum regulated by the complex feedback mechanisms of the hypothalamic-pituitary-ovarian (HPO) axis [1]. Under

optimal conditions, the pulsatile secretion of Gonadotropin-Releasing Hormone (GnRH) from the hypothalamus stimulates the anterior pituitary gland to release Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) in precise temporal rhythms [2]. These glycoproteins, in turn, drive ovarian folliculogenesis, estrogen synthesis, ovulation, and the subsequent formation of the corpus luteum [3]. Any neuroendocrine, metabolic, or structural disruption within this delicate axis can manifest clinically as a menstrual cycle disorder in women of reproductive age.

Epidemiological and Pathophysiological Burden

Menstrual cycle disorders—encompassing oligomenorrhea (infrequent menstruation), secondary amenorrhea (absence of menstruation), and abnormal uterine bleeding (AUB)—are highly prevalent, affecting an estimated 15% to 20% of the global female population in their reproductive years [4]. These disorders are rarely isolated reproductive issues; they are frequently the earliest clinical manifestations of systemic endocrine and metabolic pathologies. Among these, Polycystic Ovary Syndrome (PCOS) is the most dominant, characterized by hyperandrogenism, chronic anovulation, and polycystic ovarian morphology [5]. Furthermore, contemporary research underscores the critical role of metabolic dysfunctions, particularly insulin resistance and hyperinsulinemia, which directly amplify ovarian androgen production and disrupt follicle maturation [6]. Other significant etiological factors include thyroid dysfunction (both hypothyroidism and hyperthyroidism), hyperprolactinemia, and hypothalamic disturbances induced by chronic stress, extreme weight fluctuations, or intensive physical exertion [2].

The Paradigm Shift in Treatment Principles

Historically, standard gynecological protocols for menstrual irregularities relied heavily on the empirical prescription of combined oral contraceptives (COCs) to artificially regulate bleeding patterns and provide endometrial protection [7]. While effective for symptom control, this conventional approach merely masks the underlying ovulatory dysfunction and metabolic derangements, often leading to rapid relapse of symptoms upon discontinuation.

Modern gynecological endocrinology mandates a paradigm shift toward precision medicine. This involves precise, personalized clinical-diagnostic evaluations—utilizing advanced 3D ultrasonography, comprehensive metabolic profiling, and specific endocrine markers—to identify the exact pathophysiological mechanism [8]. By stratifying patients based on whether their dysfunction is central (hypothalamic), pituitary, ovarian, or metabolic, clinicians can implement targeted therapies. These modern modalities include the use of specific insulin sensitizers (such as myo-inositol and metformin), targeted progestins, anti-androgens, and structured lifestyle modifications aimed at restoring true spontaneous ovulation rather than establishing an artificial withdrawal bleed [9]. This study explores these modern diagnostic features and rigorously evaluates the clinical efficacy of targeted, personalized treatment principles within a controlled clinical cohort.

Material and Methods

Study Design and Patient Selection

To rigorously evaluate the efficacy of modern diagnostic and treatment modalities, a prospective, comparative, and randomized clinical study was organized. The study cohort consisted of 80 women of reproductive age, strictly between the ages of 18 and 35 (mean age 26.4 ± 3.8 years).

Inclusion Criteria: Patients presenting with chronic menstrual cycle irregularities (oligomenorrhea, amenorrhea, or AUB) persisting for more than six consecutive months; absence of organic pelvic pathology (such as large fibroids or malignancies); and a desire to restore natural ovulatory function.

Exclusion Criteria: Patients with congenital anomalies of the reproductive tract, severe chronic hepatic or renal failure, or those currently on hormone replacement therapy prior to the study.

Diagnostic Protocol

All 80 patients underwent an initial baseline evaluation consisting of a detailed medical history, physical examination (including BMI calculation and assessment of hirsutism via the Ferriman-Gallwey score), and initial pelvic ultrasonography. Hormonal assays (LH, FSH, Prolactin, Estradiol, Testosterone, TSH) were drawn precisely on days 2–5 of the spontaneous or progesterone-induced menstrual cycle.

Following initial assessment, the 80 patients were evenly and randomly divided into two study groups:

1. **The Modern Method Group (n=40):** This cohort was subjected to an extended and highly precise diagnostic protocol. This included advanced transvaginal 3D ultrasonography with Doppler color flow mapping to assess ovarian stromal vascularity. Extensive metabolic and endocrine panels were evaluated, including the HOMA-IR index for insulin resistance, Anti-Müllerian Hormone (AMH), Sex Hormone-Binding Globulin (SHBG), free testosterone, and thyroid antibodies. Treatment was strictly individualized based on the specific etiology identified. For instance, patients with insulin-resistant PCOS received myo-inositol (2000-4000 mg/day) combined with alpha-lipoic acid and cyclical micronized progesterone, while patients with stress-induced hypothalamic dysfunction received targeted neuro-metabolic support and cognitive-behavioral counseling.

2. **The Control Group (n=40):** This cohort was diagnosed and managed according to traditional standard protocols. Diagnosis relied on basic 2D pelvic ultrasound and a standard limited endocrine panel (FSH, LH, TSH). Therapeutic intervention consisted primarily of broad-spectrum standard combined oral contraceptives (ethinylestradiol + levonorgestrel) administered cyclically for six months to establish regular withdrawal bleeding, representing the conventional "symptomatic" approach.

Statistical Analysis

Clinical and laboratory data were recorded in detailed registries. Statistical analysis was performed using Python (pandas, scipy, matplotlib). Continuous variables were analyzed for normal distribution and expressed as mean ± standard deviation (M ± SD). Group comparisons were conducted using the Student's t-test for continuous variables and Chi-square ($\chi 2$) tests for categorical variables. A p-value of <0.05 was considered statistically significant.

Result and Discussion

Etiological Stratification of Menstrual Disorders

The initial diagnostic phase confirmed that "menstrual cycle disorders" is an umbrella term masking a highly heterogeneous group of pathologies. Accurate and deep diagnostic evaluation is the cornerstone of modern treatment, ensuring that therapeutic interventions are targeting the root cause.

Table 1

Etiological Classification and Pathological Drivers in the Study Cohort

Etiological Factor	Modern Method Group (n=40)	Control Group (n=40)	Total Cohort (n=80)	Percentage of Total
PCOS and Hyperandrogenism	18	19	37	46.25%

Hypothalamic-Pituitary Dysfunction	9	8	17	21.25%
Thyroid Dysfunction (Autoimmune/Subclinical)	7	6	13	16.25%
Diminished Ovarian Reserve (Premature)	4	5	9	11.25%
Idiopathic / Unexplained	2	2	4	5.00%

Extensive Clinical Explanation of Table 1:

Table 1 outlines the precise baseline distribution of the clinical diagnoses among the 80 patients before any therapeutic intervention commenced. The data clearly indicates that Polycystic Ovary Syndrome (PCOS) combined with systemic hyperandrogenism is the overwhelmingly dominant driver of menstrual cycle disorders, accounting for nearly half of all cases (46.25%). This aligns with global epidemiological data showing PCOS as the primary cause of anovulatory infertility.

Hypothalamic-pituitary dysfunction (often related to modern psychological stress, eating disorders, or hyperprolactinemia) emerged as the second most common factor (21.25%). The relatively even demographic and etiological distribution between the Modern Method and Control groups is a critical methodological strength, ensuring that any subsequent variance in treatment outcomes is statistically valid and not the result of a skewed baseline cohort. Identifying these specific subgroups was utterly vital for the Modern Method group. A patient with autoimmune thyroiditis inducing oligomenorrhea requires a completely different therapeutic protocol (e.g., levothyroxine and selenium) than a patient suffering from hyperinsulinemic PCOS, who requires insulin sensitizers. Standard OCPs would merely mask both conditions equally, failing to resolve the underlying metabolic or autoimmune crisis.

Hormonal and Metabolic Dynamics Post-Intervention

Following six months of active, monitored treatment, both groups were re-evaluated clinically and biochemically to measure the restoration of regular, ovulatory menstrual cycles and the correction of systemic endocrine markers.

Table 2

Deep Hormonal and Metabolic Profile Dynamics Pre- and Post-Treatment (Mean Values)

Clinical Marker	Modern Method (Pre-Tx)	Modern Method (Post-Tx)	Control Group (Pre-Tx)	Control Group (Post-Tx)	Statistical Significance (p-value)
Luteinizing Hormone (LH)	12.4 mIU/mL	6.8 mIU/mL	12.1 mIU/mL	9.5 mIU/mL	$p < 0.05$
Follicle-Stimulating Hormone (FSH)	5.2 mIU/mL	6.1 mIU/mL	5.4 mIU/mL	5.8 mIU/mL	$p > 0.05$
LH/FSH Ratio	2.38	1.11	2.24	1.63	$p < 0.01$
Fasting Insulin	14.5 µU/mL	8.2 µU/mL	14.1 µU/mL	12.9 µU/mL	$p < 0.01$
Free Testosterone	4.1 pg/mL	2.2 pg/mL	3.9 pg/mL	3.1 pg/mL	$p < 0.05$

Extensive Clinical Explanation of Table 2:

BG Pulse Journal USA
ISSN:1947-2536 http://www.bgpulseusa.com/index.php/bg
BG PULSE JOURNAL

Table 2 details the critical hormonal and metabolic shifts achieved after six months of respective therapies. A pathognomonic hallmark of PCOS and central menstrual disorders is a heavily elevated LH-to-FSH ratio (typically >2.0), which paralyzes follicle maturation and induces ovarian androgen hypersecretion. Before treatment, both groups displayed severely elevated LH/FSH ratios (2.38 and 2.24, respectively).


Post-treatment, the Modern Method group demonstrated a dramatic and statistically highly significant ($p < 0.01$) normalization of this ratio down to 1.11. This indicates a restoration of the physiological pulsatility of the HPO axis and the resumption of healthy ovulatory signaling. In stark contrast, the Control group, receiving standard OCPs, experienced only a mild reduction to 1.63, reflecting suppression rather than correction of the neuroendocrine axis.

Equally vital is the metabolic data. The integration of targeted metabolic therapies (e.g., inositol complexes) in the Modern Method group effectively bypassed cellular insulin resistance, leading to a massive drop in fasting insulin levels from 14.5 to a healthy 8.2 µU/mL. Because insulin directly stimulates the ovarian theca cells to produce androgens, this metabolic correction caused a parallel drop in free testosterone (from 4.1 to 2.2 pg/mL), thereby removing the toxic androgenic block on follicle development. The Control group, treated with conventional hormonal suppression, experienced minimal change in their metabolic profile (insulin dropping only to 12.9 µU/mL), underscoring the critical limitation of traditional therapies: they do not cure the metabolic syndrome that causes the disorder.

Clinical Efficacy and Cycle Restoration Tracking

To effectively visualize the superior long-term clinical efficacy of the targeted therapies, we generated a comprehensive visualization tracking the timeline of true ovulatory cycle restoration between the two cohorts.

Diagram 1



Extensive Explanation of the Diagrammatic Results:

The generated clustered bar chart provides a striking visual synthesis of the clinical outcomes for the 80 study participants. The visualization strictly categorizes patient outcomes into three

distinct tiers based on the time required to achieve spontaneous, ultrasound-confirmed ovulatory cycles.

As explicitly shown in the diagram, the **Modern Targeted Protocol Group** (green bars) achieved highly successful, rapid cycle restoration. A majority of 26 out of 40 patients (65%) achieved full ovulatory restoration within just the first 1 to 3 months of personalized treatment. Another 12 patients stabilized within 3 to 6 months. Most notably, only 2 patients (5%) in the modern group failed to show true ovulatory restoration by the end of the six-month trial.

In sharp contrast, the **Standard Conventional Protocol Group** (blue bars) exhibited a distinctly sluggish and inferior clinical response. Only 14 patients (35%) achieved rapid restoration. More concerning is the final tier: 10 out of 40 patients (a full 25% of the control cohort) failed to restore normal ovulatory function entirely, instead experiencing only artificial, chemically induced withdrawal bleeds without true ovulation. This visualization undeniably proves that deploying deep endocrine profiling alongside targeted metabolic therapies yields vastly faster, safer, and significantly more reliable clinical outcomes than broad-spectrum standard suppression protocols.

Conclusion

Menstrual cycle disorders in women of reproductive age are complex, multi-systemic pathologies that extend far beyond simple gynecological inconvenience. They represent intricate neuroendocrine and metabolic disruptions that pose severe risks to long-term fertility, cardiovascular health, and metabolic stability.

The comprehensive results of this controlled clinical study involving 80 patients definitively demonstrate that generalized, standard protocols relying on simple cycle regulation via oral contraceptives are fundamentally insufficient. Such traditional methods fail to correct underlying insulin resistance, hyperandrogenism, or thyroid dysfunction, merely masking the pathology.

Conversely, modern treatment principles—which prioritize deep etiological stratification, the aggressive correction of cellular insulin resistance, and precise, targeted hormonal balancing—yield vastly superior results. The modern approach not only normalizes critical neuroendocrine markers like the LH/FSH ratio but fundamentally alters the metabolic environment of the ovary, drastically accelerating the rate of true, spontaneous ovulatory cycle restoration. Integrating these modern clinical-diagnostic guidelines into daily gynecological practice is no longer optional; it is an absolute necessity for preserving the reproductive potential and long-term systemic health of women.

References

1. ACOG Committee on Practice Bulletins—Gynecology. (2022). Management of abnormal uterine bleeding associated with ovulatory dysfunction. *Obstetrics & Gynecology*, *122*(1), 176–185.
2. Speroff, L., & Fritz, M. A. (2020). *Clinical Gynecologic Endocrinology and Infertility* (9th ed.). Lippincott Williams & Wilkins.
3. Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S., Legro, R. S., ... & Yildiz, B. O. (2016). Polycystic ovary syndrome. *Nature Reviews Disease Primers*, *2*(1), 1-18.
4. Fraser, I. S., Critchley, H. O., Broder, M., & Munro, M. G. (2018). The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. *Seminars in Reproductive Medicine*, *29*(5), 383-390.

5. Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., ... & Yildiz, B. O. (2023). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *Human Reproduction*, *33*(9), 1602-1618.
6. Chrousos, G. P., & Kino, T. (2020). Glucocorticoid signaling in the cell: Expanding clinical implications to complex human physiologic and pathologic conditions. *Annals of the New York Academy of Sciences*, *1179*, 153–166.
7. Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2021). Polycystic ovary syndrome. *The Lancet*, *370*(9588), 685-697.
8. Diamanti-Kandarakis, E., & Dunaif, A. (2019). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. *Endocrine Reviews*, *33*(6), 981-1030.
9. Genazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Chierchia, E., Rattighieri, E., ... & Simoncini, T. (2019). Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. *Gynecological Endocrinology*, *28*(12), 969-973.